相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue
Sandrine Haghiri et al.
BONE MARROW TRANSPLANTATION (2021)
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium
Steven G. DuBois et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission
Jaume Mora et al.
PEDIATRIC BLOOD & CANCER (2021)
The Role of Surgery in High-risk Neuroblastoma
Anne L. Ryan et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2020)
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group
Rajen Mody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study
Keith Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future
Wayne H. Liang et al.
JCO CLINICAL CANCER INFORMATICS (2020)
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)
Navin Pinto et al.
EUROPEAN JOURNAL OF CANCER (2019)
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma A Randomized Clinical Trial
Julie R. Park et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
Ruth Ladenstein et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma
Sonata Jodele et al.
BONE MARROW TRANSPLANTATION (2018)
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials
Lucas Moreno et al.
PEDIATRIC BLOOD & CANCER (2017)
Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma
Daniel von Allmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody et al.
LANCET ONCOLOGY (2017)
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2017)
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials
Wendy B. London et al.
CANCER (2017)
Genetic discoveries and treatment advances in neuroblastoma
Rochelle Bagatell et al.
CURRENT OPINION IN PEDIATRICS (2016)
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
Steven G. DuBois et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG)
Margaret J. Zhou et al.
EUROPEAN JOURNAL OF CANCER (2015)
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Navin R. Pinto et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Neuroblastoma Paradigm for Precision Medicine
Meredith S. Irwin et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2015)
Role of Surgery in the Treatment of Patients With Stage 4 Neuroblastoma Age 18 Months or Older at Diagnosis
Thorsten Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group
Gregory A. Yanik et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study
Rochelle Bagatell et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project
Wendy B. London et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pediatrics: Diagnosis of Neuroblastoma
Susan E. Sharp et al.
SEMINARS IN NUCLEAR MEDICINE (2011)
Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study
Wendy B. London et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy
Philippe E. Spiess et al.
CANCER (2006)
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group
WB London et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma
A Garaventa et al.
CANCER (2003)
分享论文
